



HUTCHISON CHINA MEDITECH LIMITED

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Total Voting Rights**

**London: Wednesday, 31 December 2014:** For information purposes, Chi-Med hereby notifies the market that as at 31 December 2014, the issued share capital of the Company consisted of 53,076,676 ordinary shares of US\$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 53,076,676 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FCA's Disclosure Rules and Transparency Rules.

**Ends**

**Enquiries**

**Chi-Med** Telephone: +852 2121 8200  
Christian Hogg, CEO

**Panmure Gordon (UK) Limited** Telephone: +44 20 7886 2500  
Richard Gray  
Andrew Potts

**Citigate Dewe Rogerson** Telephone: +44 20 7638 9571  
Anthony Carlisle Mobile: +44 7973 611 888  
David Dible Mobile: +44 7967 566 919

**About Chi-Med**

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: [www.chi-med.com](http://www.chi-med.com).